March 19, 2019 — The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA…Original Article
FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
